Despite high expectations for the "molecular revolution" in biopharmaceutical research, productivity in developing new drugs has been frustratingly low. As a result, a broad variety of diseases, in both the developed and the developing worlds, are not being treated effectively.
PALO ALTO – Despite high expectations, productivity is frustratingly low in biopharmaceutical research and development. Although expenditures have increased, the number of new medicines resulting from human-genome sequencing has not. This means that a broad variety of diseases are not being treated effectively, in the developed or the developing worlds.
Advances in molecular sciences, corresponding to the sequencing of the human genome in the 1980’s, led to the identification of all the human proteins – large, complex molecules necessary for many of the body’s functions. Understanding the proteins’ roles then led to greater knowledge of the underlying causes of diseases. For example, mutations, or defects, at specific molecular locations in human DNA were found to be responsible for some cancers, raising the hope of developing successful therapies tailored to individual patients.
Scientists believed that the ability to visualize and understand human biology at a more detailed level would lead to many new medicines. Identifying the defective molecular parts, known as the drug targets, should have made addressing the causes of disease easier, and would revolutionize the pharmaceutical sciences. And so it has – but without increasing the number of new medicines.
We hope you're enjoying Project Syndicate.
To continue reading, subscribe now.
Subscribe
Get unlimited access to PS premium content, including in-depth commentaries, book reviews, exclusive interviews, On Point, the Big Picture, the PS Archive, and our annual year-ahead magazine.
Already have an account or want to create one to read two commentaries for free?
Log in
PALO ALTO – Despite high expectations, productivity is frustratingly low in biopharmaceutical research and development. Although expenditures have increased, the number of new medicines resulting from human-genome sequencing has not. This means that a broad variety of diseases are not being treated effectively, in the developed or the developing worlds.
Advances in molecular sciences, corresponding to the sequencing of the human genome in the 1980’s, led to the identification of all the human proteins – large, complex molecules necessary for many of the body’s functions. Understanding the proteins’ roles then led to greater knowledge of the underlying causes of diseases. For example, mutations, or defects, at specific molecular locations in human DNA were found to be responsible for some cancers, raising the hope of developing successful therapies tailored to individual patients.
Scientists believed that the ability to visualize and understand human biology at a more detailed level would lead to many new medicines. Identifying the defective molecular parts, known as the drug targets, should have made addressing the causes of disease easier, and would revolutionize the pharmaceutical sciences. And so it has – but without increasing the number of new medicines.
We hope you're enjoying Project Syndicate.
To continue reading, subscribe now.
Subscribe
Get unlimited access to PS premium content, including in-depth commentaries, book reviews, exclusive interviews, On Point, the Big Picture, the PS Archive, and our annual year-ahead magazine.
Already have an account or want to create one to read two commentaries for free? Log in